SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying...
5 insider purchases on record · latest filing 2023-12-08.
Insiders have also filed 1 sale transaction at SABS.